Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 AstraZeneca 3Q | Contract Pharma

What are you searching for?

Sign in
Breaking News, Financial News

AstraZeneca 3Q

Sales of Influenza A (H1N1) vaccine totaled $152 million in the quarter. Nexium sales were down 5% to $1.2 billion.

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

AstraZeneca 3Q09

3Q Revenues: $8.2 billion (+5%)

3Q Earnings: $2.1 billion (+27%)

YTD Revenues: $23.9 billion (+2%)

YTD Earnings: $6.0 billion (+27%)

Comments: Sales of Influenza A (H1N1) vaccine totaled $152 million in the quarter. Nexium sales were down 5% to $1.2 billion. Crestor sales were $1.1 billion (+24%). Seloken /Toprol-XL sales were $414 million (+103%). Symbicort sales were $562 million (+12%). Seroquel sales were $1.2 billion (+9%). Casodex sales in the U.S. were down 80% to $14 million following FDA approval of eight generic products. U.S. revenue was up 14%. Revenue in the Rest of World was up 7%. Revenue in Established Markets was up 4% and Emerging Markets was up 15%. In the quarter, diabetes treatment Onglyza was approved in the U.S. and EU.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters